Literature DB >> 17360887

Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.

Willy K Tonui1, Richard G Titus.   

Abstract

Vaccinating with soluble Leishmania major promastigote exogenous antigens (LmSEAgs) protects mice against challenge with L. major. To explore the potential of LmSEAgs to cross-protect against infection with other species of Leishmania, BALB/c mice were immunized with LmSEAgs prior to challenge with either L. donovani or L. braziliensis promastigotes. Such mice were protected against L. donovani but not L. braziliensis infection. Leishmania braziliensis-infected mice developed lesions that were not significantly different from those of controls and that contained 13-fold more parasites. In contrast, immunized mice infected with L. donovani were protected as illustrated by low splenic parasite loads (as much as 4,913-fold fewer parasites). This protection corresponded to significant increases in gamma interferon and low production of interleukin-4 (IL-4) IL-4 or IL-10, which suggested an enhanced type 1 response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360887

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

2.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

Review 3.  Drug discovery algorithm for cutaneous leishmaniasis.

Authors:  Max Grogl; Mark Hickman; William Ellis; Thomas Hudson; John S Lazo; Elizabeth R Sharlow; Jacob Johnson; Jonathan Berman; Richard J Sciotti
Journal:  Am J Trop Med Hyg       Date:  2013-02       Impact factor: 2.345

4.  The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas.

Authors:  Kristina M Bacon; Peter J Hotez; Stephanie D Kruchten; Shaden Kamhawi; Maria Elena Bottazzi; Jesus G Valenzuela; Bruce Y Lee
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

Review 5.  Understanding Leishmania parasites through proteomics and implications for the clinic.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Proteomics       Date:  2018-05-02       Impact factor: 3.940

6.  TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Authors:  Asha Jayakumar; Tiago M Castilho; Esther Park; Karen Goldsmith-Pestana; Jenefer M Blackwell; Diane McMahon-Pratt
Journal:  PLoS Negl Trop Dis       Date:  2011-06-14

7.  Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.

Authors:  Diego M Santos; Marcia W Carneiro; Tatiana R de Moura; Kiyoshi Fukutani; Jorge Clarencio; Manuel Soto; Socorro Espuelas; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Camila I de Oliveira
Journal:  Int J Nanomedicine       Date:  2012-04-24

Review 8.  Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.

Authors:  Sreenivas Gannavaram; Ranadhir Dey; Kumar Avishek; Angamuthu Selvapandiyan; Poonam Salotra; Hira L Nakhasi
Journal:  Front Immunol       Date:  2014-05-23       Impact factor: 7.561

9.  In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.

Authors:  Rym Chamakh-Ayari; Rachel Bras-Gonçalves; Narges Bahi-Jaber; Elodie Petitdidier; Wafa Markikou-Ouni; Karim Aoun; Javier Moreno; Eugenia Carrillo; Poonam Salotra; Himanshu Kaushal; Narender Singh Negi; Jorge Arevalo; Francesca Falconi-Agapito; Angela Privat; Maria Cruz; Julie Pagniez; Gérard-Marie Papierok; Faten Bel Haj Rhouma; Pilar Torres; Jean-Loup Lemesre; Mehdi Chenik; Amel Meddeb-Garnaoui
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 10.  A review of the leishmanin skin test: A neglected test for a neglected disease.

Authors:  Jessica Carstens-Kass; Kayla Paulini; Patrick Lypaczewski; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.